Sandoz Gets Early Win In Amgen IP Dispute Over Neulasta
A California federal judge gave Sandoz Inc. a quick win Tuesday in a patent infringement suit brought by Amgen Inc. over the biologic Neulasta, finding Sandoz's biosimilar doesn't infringe Amgen's formula....To view the full article, register now.
Already a subscriber? Click here to view full article